Valion Bio, Inc. Balance Sheet
VBIO|3 years of annual SEC 10-K data (FY2022-FY2024)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 3 fiscal years. All figures from audited SEC 10-K filings.
Valion Bio, Inc. had $3M in total assets and $4M in shareholders' equity as of FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -10.05 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Cash & Equivalents | $2.0M | $3.4M | $3.5M |
| Accounts Receivable | $69.0K | $174.0K | $88.0K |
| Inventory | $319.0K | $756.0K | $863.0K |
| Current Assets | $2.6M | $4.7M | $5.3M |
| PP&E (Net) | $119.0K | $122.0K | $12.0K |
| Total Assets | $2.8M | $5.2M | $5.9M |
| Current Liabilities | $272.0K | $1.4M | $1.9M |
| Shareholders' Equity | $3.6M | $3.6M | $13.3M |